Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

After 10years of JAK2V617F: Disease biology and current management strategies in polycythaemia vera.

Blood reviews - 1 May 2017

Grinfeld Jacob, Godfrey Anna L

Abstract excerpt

The JAK2V617F mutation accounts for the vast majority of patients with polycythaemia vera (PV) and around half of those with other Philadelphia-negative myeloproliferative neoplasms. Since its discovery in 2005, numerous insights have been gained into the pathways by which JAK2V617F causes myeloproliferation, including activation of JAK-STAT signalling but also through other canonical and non-canonical pathways....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amino Acid Substitution
Share to Cell Transformation, Neoplastic
Share to Disease Management

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Expression Regulation

Share to Hematopoietic Stem Cells

Share to Janus Kinase 2

Share to Myeloproliferative Disorders

Share to Polycythemia Vera

Source

Identifiers

PMID: 27884555
DOI: 10.1016/j.blre.2016.11.001

Genes

JAK2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

After 10years of JAK2V617F: Disease biology and current management strategies in polycythaemia vera.PMID 27884555Read ↗

Classification, Diagnosis and Management of Myeloproliferative Disorders in the JAK2V617F EraSemantic proximity Read ↗

JAK2 V617F allele burden in polycythemia vera: burden of proof.Semantic proximity Read ↗

Genetic Background of Polycythemia Vera.Semantic proximity Read ↗

Polycythemia vera: diagnosis, clinical course, and current managementSemantic proximity Read ↗

The JAK2 mutation.Semantic proximity Read ↗

Role of JAK-STAT Signaling in the Pathogenesis of Myeloproliferative DisordersSemantic proximity Read ↗

Polycythemia vera: from new, modified diagnostic criteria to new therapeutic approaches.Semantic proximity Read ↗

Polycythaemia vera: molecular genetics, diagnostics and therapeutics.Semantic proximity Read ↗

Polycythemia vera.Semantic proximity Read ↗

The JAK2V617F mutation in polycythemia vera and other myeloproliferative disorders: one mutation for three diseases?Semantic proximity Read ↗

Narrative review: Thrombocytosis, polycythemia vera, and JAK2 mutations: The phenotypic mimicry of chronic myeloproliferation.Semantic proximity Read ↗

JAK-2 mutations and their relevance to myeloproliferative diseaseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.